Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
McGill University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
McGill University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
McGill University, Medical Devices Deals, 2012 to YTD 2018 10
McGill University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
McGill University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Lead Discovery Center Enters into Research Agreement with McGill University 13
Proove Biosciences Enters into Partnership with McGill University 14
B Cell Design Enters into R&D Agreement with McGill University 15
IASO BioMed Enters into Research Agreement with Research Institute of the McGill University 16
Cyclenium Pharma Enters into Research Agreement with McGill University 17
Neomed Institute Partners with McGill University 18
MSBi Valorisation, McGill University and Research Institute of the McGill University Health Centre Form Partnership 19
Viteava Pharma Enters Into Research Agreement With Mcgill University 20
Licensing Agreements 21
Aptorum Therapeutics Enters into Licensing Agreement with PolyU Technology and Consultancy, McGill University, Wayne State University, Moffitt Cancer Center and CUHK 21
Corbin Therapeutics Enters into License Agreement with McGill University 23
Domain Therapeutics Extends Licensing Agreement with Universite de Montreal and McGill University 24
IASO BioMed Enters into Licensing Agreement with McGill University 26
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 27
AUM LifeTech Enters into Licensing Agreement with McGill University 28
PsychoGenics Enters into Licensing Agreement with McGill University for McGill-R-Thy I-APP 29
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 30
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 32
Asset Transactions 33
Kanyr Pharma Acquires Rights for Two Cancer Programs from McGill University 33
McGill University – Key Competitors 34
McGill University – Key Employees 35
McGill University – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Strategy And Business Planning 37
Jan 09, 2017: Amorchem Spins Out Its USP15-deubiquitinylation (DUB) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M $ Seed Investment 37
Government and Public Interest 38
Aug 16, 2018: The Government of Quebec Grants $500,000 to McGill University and RI-MUHC to Support Two Collaborative Projects 38
Jun 19, 2018: Alzheimer Society Research Program awards $2.9 million to Canadian researchers 39
May 07, 2018: A new molecular target identified in depression 40
May 03, 2018: Early HIV treatment key to avoiding brain atrophy 41
Apr 26, 2018: Extraordinary $15-million gift will create unique powerhouse initiative to fight infections 42
Mar 08, 2018: Canadian researchers open a new front in the fight against MS 44
Mar 01, 2018: A near-universal way to measure enzyme inhibition 45
Feb 21, 2018: McGill-led genomics centres win $9.8 M, three-year funding support from Genome Canada 46
Feb 20, 2018: Products derived from plants offer potential as dual-targeting agents for experimental cerebral malaria 47
Feb 19, 2018: Government of Canada and Brain Canada announce a $10-million grant to establish a platform that will help researchers share data more widely and efficiently 48
Jan 31, 2018: McGill research team studies how calcium compounds accumulate in the arteries 49
Jan 30, 2018: Epigenetic alteration of a vitamin B12 processing gene shines new light on our understanding of rare diseases 51
Jan 11, 2018: Progression of Parkinson’s disease follows brain connectivity 52
Oct 23, 2017: Transformative donation of $16 million establishes new autism research centre at the Montreal Neurological Institute 53
Oct 13, 2017: New mechanism detected in Alzheimer’s disease 54
Oct 13, 2017: Neurotechnological innovation and organ-on-a-chip engineering centres receive more than $10 million in new funding 55
Sep 06, 2017: Scientists link 153 new genetic variants to osteoporosis in largest ever study 56
May 15, 2017: Diabetes drug may help symptoms of autism associated condition 57
Jan 09, 2017: Breakthrough in MS treatment 58
Product News 59
Jul 10, 2018: Unique brain “fingerprint” can predict drug effectiveness 59
Other Significant Developments 60
Jul 04, 2018: Pathway of Alzheimer’s degeneration discovered 60
Jul 04, 2018: HPV testing could be more accurate than smear tests for initial screening of cervical cancer 61
Apr 25, 2018: Quebec patients poised to benefit from major investments in genomics research and precision health 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
McGill University, Pharmaceuticals & Healthcare, Key Facts 2
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
McGill University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
McGill University, Deals By Therapy Area, 2012 to YTD 2018 9
McGill University, Medical Devices Deals, 2012 to YTD 2018 10
McGill University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lead Discovery Center Enters into Research Agreement with McGill University 13
Proove Biosciences Enters into Partnership with McGill University 14
B Cell Design Enters into R&D Agreement with McGill University 15
IASO BioMed Enters into Research Agreement with Research Institute of the McGill University 16
Cyclenium Pharma Enters into Research Agreement with McGill University 17
Neomed Institute Partners with McGill University 18
MSBi Valorisation, McGill University and Research Institute of the McGill University Health Centre Form Partnership 19
Viteava Pharma Enters Into Research Agreement With Mcgill University 20
Aptorum Therapeutics Enters into Licensing Agreement with PolyU Technology and Consultancy, McGill University, Wayne State University, Moffitt Cancer Center and CUHK 21
Corbin Therapeutics Enters into License Agreement with McGill University 23
Domain Therapeutics Extends Licensing Agreement with Universite de Montreal and McGill University 24
IASO BioMed Enters into Licensing Agreement with McGill University 26
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 27
AUM LifeTech Enters into Licensing Agreement with McGill University 28
PsychoGenics Enters into Licensing Agreement with McGill University for McGill-R-Thy I-APP 29
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 30
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 32
Kanyr Pharma Acquires Rights for Two Cancer Programs from McGill University 33
McGill University, Key Competitors 34
McGill University, Key Employees 35
McGill University, Subsidiaries 36
McGill University, Joint Venture 36
List of Figures
McGill University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
McGill University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
McGill University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
McGill University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
McGill University, Medical Devices Deals, 2012 to YTD 2018 10
